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Abstract Angiotensin II (Ang II), a potent hypertrophic factor 
for vascular smooth muscle cells (VSMC), induces activation of 
the ras  proto-oncogene product (Ras) and mitogen-activated 
protein (MAP) kinases, and tyrosine phosphorylation of a focal 
adhesion-associated protein, paxillin. Forskolin, a direct activa- 
tor of adenylate cyclase, and dibutyryl cAMP (Bt2 cAMP), a 
membrane permeable cAMP analogue, potently inhibited Ang II- 
stimulated protein synthesis. However, they did not inhibit Ang 
II-induced activation of Ras and MAP kinases. Although both 
forskolin and Bt2 cAMP potently reduced background tyrosine 
phosphorylation of paxillin, they allowed Ang II to induce the 
same reaction. These results indicate that increasing cAMP 
antagonizes the hypertrophic response to Ang II without 
affecting Ras and MAP kinase activation in VSMC and suggest 
that it does not interrupt signaling from the Ang II receptor to 
focal adhesions. 
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Graves et al. [16] reported that increasing intracellular 
cAMP attenuates PDGF-induced MAP kinase activation in 
human VSMC. Since the MAP kinase cascade plays a critical 
role in growth factor-induced cell proliferation [17], the inhi- 
bition of MAP kinase activation by cAMP is considered to be 
one of the mechanisms of anti-proliferative action of this nu- 
cleotide. Moreover, cAMP-mediated inhibition of MAP ki- 
nase activation has been observed in various cell types stimu- 
lated by their respective agonists [17]. Therefore, in the 
present study, we addressed the question as to whether eleva- 
tion in intracellular cAMP analogously attenuates Ang II-in- 
duced MAP kinase activation and then inhibits the hyper- 
trophic response of VSMC. This paper reports that 
increasing cAMP potently inhibits Ang II-stimulated hyper- 
trophy as assessed by protein synthesis but does not affect 
Ang II-induced activation of Ras and MAP kinases in rat 
VSMC. The effect of increasing cAMP on tyrosine phosphor- 
ylation of pa×illin is also described. 
1. Introduction 
Angiotensin II (Ang II) has been shown to induce cell hy- 
pertrophy as a result of increased protein synthesis rather 
than cell proliferation in cultured vascular smooth muscle 
cells (VSMC) [1,2]. Since this growth promoting action of 
Ang II is considered to contribute to the development of 
various vascular diseases, particularly, vascular remodeling 
observed in hypertension, it is important to clarify how the 
hypertrophic action of Ang II is regulated. 
Ang lI acts via a high affinity cell surface receptor called the 
AT1 receptor. Although this receptor is a seven transmem- 
brane, heterotrimeric G protein-coupled receptor, many of 
the intracellular signals mediated by the AT1 receptor are 
similar to the signaling pathways activated by receptor tyro- 
sine kinases such as platelet-derived growth factor (PDGF) 
and epidermal growth factor (EGF) receptors. For instance, 
Ang II induces activation of the ras proto-oncogene product 
(Ras) [3-5], tyrosine and threonine phosphorylation a d acti- 
vation of mitogen-activated protein (MAP) kinases [6], expres- 
sing early growth response genes such as c-fos, c-jun and c- 
myc [7-9] and tyrosine phosphorylation f a focal adhesion- 
associated protein, paxillin [10-12]. These intracellular events 
are considered to be involved in the growth promoting action 
of Ang II. Less is known, however, about negative regulatory 
mechanisms for the hypertrophic response to Ang II. 
Elevation in intracellular cAMP potently inhibits growth 
factor-induced proliferation of VSMC [13 15]. Recently, 
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2. Materials and methods 
2.1. Materials 
Ang II, forskolin, dibutyryl cAMP (Bt2 cAMP) and myelin basic 
protein (MBP) were obtained from Sigma (St. Louis, MO, USA). The 
anti-Ras rat monoclonal ntibody Y13-259, anti-MAP kinase mouse 
monoclonal ntibody, anti-paxillin mouse monoclonal ntibody, and 
anti-phosphotyrosine monoclonal ntibody PY-20 were obtained from 
Oncogene Science (Cambridge, MA, USA), Zymed Laboratories (San 
Francisco, CA, USA), Transduction Laboratories (Lexington, KY, 
USA), and ICN (Costa Mesa, CA, LISA), respectively. L-[4,5- 
:~H]Leucine (139 Ci/mmol), [7-32p]ATP (3000 Ci/mmol) and peroxi- 
dase-labeled sheep anti-mouse IgG were from Amersham Life Science 
(Tokyo, Japan). [32p]Orthophosphate was from Du Pont (Boston, 
MA, USA). Protein A-Sepharose 4 Fast Flow was from Pharmacia 
(Uppsala, Sweden). Rabbit antiserum to rat IgG and affinity-purified 
rabbit anti-mouse IgG were from Cappel (Durham, NC, USA) and 
Jackson ImmunoResearch Laboratories (West Grove, PA, USA), re- 
spectively. Other materials and chemicals were obtained from com- 
mercial sources. 
2.2. Cell culture 
VSMC were isolated from rat thoracic aorta by enzymatic dissocia- 
tion as described previously [18]. Cells were grown and passaged as 
described previously [19] and used at passage l vels 8 16. 
2.3. Protein synthesks assay 
Protein synthesis was measured by [;~H]leucine incorporation as 
described previously [2]. The quiescent VSMC in triplicate wells of 
24-well plates were stimulated with Ang II in serum-free Dulbecco's 
modified Eagle's medium (DMEM) containing 0.5 laCi/ml [aH]leucine. 
After 24 h, the medium was aspirated. Cells were washed three times 
with ice-cold phosphate-buffered saline, and incubated with 5% tri- 
chloroacetic acid at 4°C for 30 min. Trichloroacetic a id precipitable 
materials were washed twice with 5% trichloroacetic a id and solubi- 
lized in 0.1 N NaOH at 37°C for 30 rain. The radioactivity was 
measured by liquid scintillation spectrometry. 
All rights reserved. 
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2.4. Analysis' of Ras-bound GDP and GTP 
Detection and quantification of Ras-bound GDP and GTP were 
performed as described previously [3]. Briefly, the quiescent VSMC 
on 60-mm dishes were incubated with phosphate-free DMEM supple- 
mented with 0.2 mCi/ml [a2P]orthophosphate for 12 h. 50 gM sodium 
orthovanadate was added to the cells during the last 30 min. After 
stimulation with Ang II, the cells were lysed. Ras was immunoprecip- 
itated from the cell lysates with anti-Ras monoclonal antibody Y13- 
259 and analyzed by thin-layer chromatography. 
2.5. MAP kinase assay in polyacrylarnide gel containing MBP 
MAP kinase activity was measured by a MAP kinase renaturation 
assay in MBP-containing polyacrylamide g ls as described previously 
[3]. Briefly, the cell lysates from VSMC stimulated with Ang II were 
subjected to SDS-polyacrylamide g lelectrophoresis (10% gel contain- 
ing 0.5 mg/ml MBP). After washing the gel with 50 mM Tris-C1, pH 
8.0, and 20% 2-propanol, and then with 50 mM Tris-C1, pH 8.0, and 5 
mM 2-mercaptoethanol (buffer A) to remove SDS, the enzymes were 
denatured by treating the gel with 6 M guanidine HCI and then 
renatured with buffer A containing 0.04% Tween 40. The gel was 
incubated at 22°C for 1 h with 40 mM HEPES, pH 8.0, 2 mM 1,4- 
dithiothreitol, 0.1 mM EGTA, 5 mM MgCI2, and 25 mM [7-32p]ATP 
(1×105 cpm/nmol) for kinase reactions. The gel was extensively 
washed with 5% trichloroacetic a id containing 1% sodium pyrophos- 
phate, dried, and the radioactivity was analyzed using a Fujix 
BAS2000 bio-imaging analyzer. 
2.6. Imrnunoprecipitation with anti-paxillin antibody and immunoblot 
with anti-phosphotyrosine a tibody 
Detection and quantification of tyrosine phosphorylation f paxillin 
was performed as described previously [10] with slight modifications. 
Briefly, VSMC stimulated with Ang II were lysed in a buffer contain- 
ing 50 mM HEPES, pH 7.6, 1% Triton X-100, 1 mM phenylmethyl- 
sulfonyl fluoride, 1 mM Na3VO4 and 100 KIU/ml aprotinin. After 
brief centrifugation, the supernatant was mixed with anti-paxillin anti- 
body for 2 h at 4°C. Immunocomplexes were precipitated for 1 h at 
4°C with Sepharose A-linked anti-mouse IgG. Paxillin immunoprecip- 
itates were separated on SDS-polyacrylamide gel electrophoresis 
(10% gel). The separated proteins were electrophoretically transferred 
to polyvinylidene diftuoride membranes. Blots were incubated with 
the anti-phosphotyrosine antibody and then incubated with peroxi- 
dase-labeled donkey anti-mouse IgG. Peroxidase-labeled proteins 
were visualized by enhanced chemiluminescence (Amersham Life 
Science). Stained protein bands were scanned by NIH image software 
interfaced with a personal computer for quantification. 
3. Results 
In agreement with previous observations [2], Ang II stimu- 
lated protein synthesis in VSMC with a half-maximal effect 
observed at ,,, 1 nM (Fig. IA). No effect on DNA synthesis as 
measured by [3H]thymidine incorporation was observed in 
these cells (data not shown). Pretreatment of cells with for- 
skolin, a direct activator of adenylate cyclase, potently inhib- 
ited Ang II-induced protein synthesis (Fig. 1A). Bt2 cAMP, a 
membrane permeable cAMP analogue, also inhibited Ang II- 
induced protein synthesis (Fig. 1B). These results indicate that 
elevation in intracellular cAMP antagonizes the hypertrophic 
response to Ang II in VSMC. 
To gain insight into the mechanisms of this anti-hyper- 
trophic action of cAMP, we next examined the effects of for- 
skolin and Bt2 cAMP on Ang II-induced activation of Ras 
and MAP kinases, both of which are considered to be in- 
volved in the growth-promoting action of Ang II. As has 
been previously described [3], Ang II induced Ras activation 
as demonstrated by an increase in the GTP-bound form of 
Ras (Fig. 2). Forskolin alone had no effect on Ras activation. 
In contrast to its inhibitory effect on protein synthesis, for- 
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Fig. 1. Effect of increasing cAMP on Ang II-induced protein syn- 
thesis. Cultured VSMC were pretreated for 15 min with or without 
forskolin or Bt2 cAMP and then stimulated with the indicated con- 
centrations of Ang II for 24 h. Protein synthesis was measured by 
[~H]leucine incorporation. Values shown are the mean _+ standard er- 
ror of the mean (S.E.M.) of three independent trials. (A) Cells were 
pretreated with vehicle (O), 10 IaM (O) or 100 [aM (n) forskolin. (B) 
Cells were pretreated with vehicle (©), I00 gM (e), 1000 gM ([]) 
Bt2 cAMP. 
bound form of Ras. Ang II also stimulated the enzymatic 
activity of MAP kinases in a dose-dependent manner (Fig. 
3). Also, forskolin did not influence the dose dependence of 
Ang II to stimulate MAP kinase activity. Pretreatment of the 
cells with Bt2 cAMP affected neither Ang II-induced Ras ac- 
tivation nor Ang II-induced MAP kinase activation (data not 
shown). 
We [10] and others [11,12] have previously shown that Ang 
II transduces its signals not only to the nucleus but also to 
focal adhesions and stimulates tyrosine phosphorylation of 
paxillin. In accord with previously published results [10], tyr- 
osine phosphorylation of paxillin was significantly elevated in 
control unstimulated VSMC (Fig. 4). Ang II consistently in- 
creased tyrosine phosphorylation levels of this protein. Pre- 
treatment of the cells with forskolin potently reduced back- 
ground tyrosine phosphorylation of paxillin. Ang II, however, 
could stimulate its tyrosine phosphorylation even in the pres- 
ence of forskolin. Pretreatment of the cells with Bt2 cAMP 
also reduced background tyrosine phosphorylation of paxillin 
but allowed Ang II to stimulate the same reaction (data not 
shown). 
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4. Discussion 
Since VSMC are capable of two distinct growth responses, 
hypertrophy and proliferation, it is important to clarify the 
regulatory mechanisms not only of proliferation but also of 
hypertrophy in order to understand the pathogenesis of var- 
ious vascular diseases characterized by abnormal VSMC 
growth. It has long been appreciated that elevation of intra- 
cellular cAMP, a second messenger for VSMC relaxation, 
inhibits growth factor-induced proliferation of VSMC [13 
15]. We [201 and others [21] have reported previously that 
elevation of intracellular cGMP, another second messenger 
for VSMC relaxation, also inhibits proliferation of VSMC. 
Itoh et al. [22] reported that increasing cGMP by atrial na- 
triuretic peptide (ANP) potently inhibited Ang II-induced 
VSMC hypertrophy. However, it has not yet been reported 
whether increasing cAMP analogously inhibits Ang II-in- 
duced VSMC hypertrophy. In the present study, we first ad- 
dressed this question and found that increasing cAMP po- 
tently inhibits Ang II-induced VSMC hypertrophy. 
Therefore, it is likely that both distinct growth responses of 
VSMC, hypertrophy and proliferation, may be negatively 
modulated not only by cGMP-elevating vasodilators such as 
nitric oxide and ANP but also by cAMP-elevating vasodila- 
tors such as prostacyclin and adrenomedullin. 
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Fig. 3. Effect of forskolin on Ang II-induced MAP kinase activa- 
tion. Cultured VSMC were pretreated for 15 min with or without 
100 I.tM forskolin and then stimulated with the indicated concentra- 
tions of Ang II for 5 min. Cell extracts were subjected to the kinase 
assay in polyacrylamide g l containing MBP. (A) The enzyme activ- 
ity was detected in both 42- and 44-kDa bands in the gel. (B) Cells 
were pretreated with vehicle (O) or 100 laM (o) of forskolin. The 
radioactivities of phosphorylated MBP at positions of MAP kinases 
were quantified using the Fujix BAS2000. Values shown are the 
mean + S.E.M. of four independent trials and are expressed as the 
percentage of the unstimulated levels. 
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Fig. 2. Effect of forskolin on Ang II-induced Ras activation. VSMC 
labeled with [32P]orthophosphate were pretreated for 15 min with or 
without 100 [aM forskolin and then stimulated with the indicated 
concentrations of Ang II for 2 rain. After lysis of the cells, Ras was 
immunoprecipitated an  analyzed. (A) Positions of GDP and GTP 
are indicated. (B) Quantification of Ras activation (GTP/ 
(GDP+GTP)) was performed using the Fujix BAS2000. Values 
shown are the mean _+ S.E.M. of three independent trials and are ex- 
pressed as the percentage of the response to 100 nM Ang II. 
MAP kinases are a family of serine-threonine kinases that 
are rapidly activated in response to a variety of growth factors 
such as PDGF and EGF in various cell types and are believed 
to play a critical role in the control of cell growth [17]. Recent 
studies have shown that MAP kinase activation by growth 
factors involves sequential activation of Ras and the proto- 
oncogene serine kinase Raf. Activated Raf then phosphory- 
lates MAP kinase kinase (MEK-1), which in turn phosphor- 
ylates and activates MAP kinase. Recently, we [3,6] and 
others [4,5] have shown that Ang II also induces activation 
of Ras and MAP kinases in VSMC. To determine whether the 
anti-hypertrophic a tion of cAMP might be mediated via in- 
hibition of the MAP kinase pathway, we examined the effects 
of forskolin and Bt2 cAMP on Ang II-induced activation of 
Ras and MAP kinases. Our observation that these cAMP- 
elevating agents had no effect on Ang II-induced activation 
of Ras and MAP kinases indicates that the inhibition of MAP 
kinases is not necessary for the anti-hypertrophic a tion of 
cAMP and suggest hat increasing intracellular cAMP may 
inhibit the step(s) downstream of MAP kinases in the MAP 
kinase-mediated pathway or the step(s) in the parallel path- 
way(s) that is/are independent of MAP kinase activation. 
Paxillin is a 68-kDa protein that binds to the cytoskeleton 
protein vinculin and localizes to focal adhesions. Although the 
precise role of tyrosine phosphorylation of paxillin is un- 
known at present, its localization suggests that tyrosine phos- 
phorylation of paxillin has a potential role in the processes 
that regulate cell adhesion, motility and growth via the ar- 
rangement of the actin cytoskeleton [23]. In the last experi- 
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Fig. 4. Effect of forskolin on Ang II-induced tyrosine phosphoryla- 
tion of paxillin. Cultured VSMC were pretreated for 15 min with or 
without 100 gM forskolin and then stimulated with the indicated 
concentrations of Ang II for 10 min. Cell extracts were subjected to 
immunoprecipitation a alysis with anti-paxillin antibody. Immuno- 
precipitates were analyzed by immunoblotting with anti-phosphotyr- 
osine antibody. (A) Positions of paxillin and immunoglobulin G
heavy chain (IgG) are indicated. (B) Cells were pretreated with vehi- 
cle (O) or 100 I.tM (e) of forskolin. Tyrosine phosphorylation of 
paxillin was quantified by scanning densitometry. Values shown are 
the mean + S.E.M. of three independent trials and expressed as the 
percentage of the response to 100 nM Ang II. 
ment of the present study, we showed that, although forskolin 
and Bt2 cAMP potently inhibited the basal level of tyrosine 
phosphorylation of paxillin, they allowed Ang II-induced 
stimulation of the same reaction, suggesting that cAMP may 
not interrupt signaling from the AT1 receptor to focal adhe- 
sions. Since background tyrosine phosphorylation of paxillin 
may be maintained, at least in part, by integrin-mediated stim- 
ulation by the extracellular matrix, it is possible that increas- 
ing cAMP negatively modulates the hypertrophic response of 
VSMC by interrupting signaling from the extracellular matrix 
via integrins. Further studies are needed to clarify the mech- 
anisms of the anti-hypertrophic a tion of cAMP. 
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